Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Jump Financial LLC

Jump Financial LLC lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 260.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,865 shares of the life sciences company's stock after buying an additional 5,680 shares during the period. Jump Financial LLC's holdings in Illumina were worth $1,051,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. M&T Bank Corp increased its position in shares of Illumina by 3.4% during the 3rd quarter. M&T Bank Corp now owns 54,378 shares of the life sciences company's stock worth $7,091,000 after purchasing an additional 1,769 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Illumina in the 3rd quarter valued at approximately $772,000. Tidal Investments LLC lifted its holdings in shares of Illumina by 38.0% in the 3rd quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company's stock worth $580,000 after acquiring an additional 1,226 shares during the last quarter. B. Riley Wealth Advisors Inc. boosted its position in shares of Illumina by 66.8% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company's stock worth $1,582,000 after purchasing an additional 4,797 shares during the period. Finally, Versant Capital Management Inc increased its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 0.3 %

Shares of NASDAQ:ILMN traded down $0.20 during trading on Friday, reaching $77.41. 973,761 shares of the stock were exchanged, compared to its average volume of 2,275,489. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The firm's 50-day moving average price is $82.50 and its 200 day moving average price is $118.63. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The firm has a market cap of $12.25 billion, a price-to-earnings ratio of -10.08, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of research analyst reports. Citigroup lowered their target price on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a report on Monday, April 7th. HSBC downgraded Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a report on Friday, February 28th. Barclays reduced their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a report on Thursday, April 10th. Hsbc Global Res cut Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Guggenheim decreased their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Illumina currently has a consensus rating of "Moderate Buy" and an average price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.